nodes	percent_of_prediction	percent_of_DWPC	metapath
Metaxalone—Gastrointestinal tract irritation—Capecitabine—kidney cancer	0.039	0.039	CcSEcCtD
Metaxalone—Haemolytic anaemia—Erlotinib—kidney cancer	0.0235	0.0235	CcSEcCtD
Metaxalone—Irritability—Everolimus—kidney cancer	0.021	0.021	CcSEcCtD
Metaxalone—Jaundice—Pazopanib—kidney cancer	0.0209	0.0209	CcSEcCtD
Metaxalone—Jaundice—Everolimus—kidney cancer	0.0165	0.0165	CcSEcCtD
Metaxalone—Leukopenia—Temsirolimus—kidney cancer	0.0159	0.0159	CcSEcCtD
Metaxalone—Abdominal discomfort—Sorafenib—kidney cancer	0.0158	0.0158	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Gemcitabine—kidney cancer	0.0152	0.0152	CcSEcCtD
Metaxalone—Abdominal discomfort—Sunitinib—kidney cancer	0.0152	0.0152	CcSEcCtD
Metaxalone—Leukopenia—Pazopanib—kidney cancer	0.015	0.015	CcSEcCtD
Metaxalone—Anaphylactic shock—Temsirolimus—kidney cancer	0.0145	0.0145	CcSEcCtD
Metaxalone—Jaundice—Sorafenib—kidney cancer	0.0143	0.0143	CcSEcCtD
Metaxalone—Somnolence—Temsirolimus—kidney cancer	0.0129	0.0129	CcSEcCtD
Metaxalone—Somnolence—Pazopanib—kidney cancer	0.0121	0.0121	CcSEcCtD
Metaxalone—Leukopenia—Vinblastine—kidney cancer	0.0119	0.0119	CcSEcCtD
Metaxalone—Leukopenia—Everolimus—kidney cancer	0.0118	0.0118	CcSEcCtD
Metaxalone—Haemolytic anaemia—Capecitabine—kidney cancer	0.0112	0.0112	CcSEcCtD
Metaxalone—Hypersensitivity—Temsirolimus—kidney cancer	0.0107	0.0107	CcSEcCtD
Metaxalone—Leukopenia—Sorafenib—kidney cancer	0.0103	0.0103	CcSEcCtD
Metaxalone—Pruritus—Temsirolimus—kidney cancer	0.0103	0.0103	CcSEcCtD
Metaxalone—Leukopenia—Sunitinib—kidney cancer	0.00988	0.00988	CcSEcCtD
Metaxalone—Pruritus—Pazopanib—kidney cancer	0.00967	0.00967	CcSEcCtD
Metaxalone—Irritability—Capecitabine—kidney cancer	0.00965	0.00965	CcSEcCtD
Metaxalone—Somnolence—Everolimus—kidney cancer	0.00959	0.00959	CcSEcCtD
Metaxalone—Dizziness—Temsirolimus—kidney cancer	0.00959	0.00959	CcSEcCtD
Metaxalone—Anaphylactic shock—Sorafenib—kidney cancer	0.00937	0.00937	CcSEcCtD
Metaxalone—Leukopenia—Dactinomycin—kidney cancer	0.00936	0.00936	CcSEcCtD
Metaxalone—Vomiting—Temsirolimus—kidney cancer	0.00922	0.00922	CcSEcCtD
Metaxalone—Rash—Temsirolimus—kidney cancer	0.00915	0.00915	CcSEcCtD
Metaxalone—Dermatitis—Temsirolimus—kidney cancer	0.00914	0.00914	CcSEcCtD
Metaxalone—Headache—Temsirolimus—kidney cancer	0.00909	0.00909	CcSEcCtD
Metaxalone—Dizziness—Pazopanib—kidney cancer	0.00904	0.00904	CcSEcCtD
Metaxalone—Vomiting—Pazopanib—kidney cancer	0.00869	0.00869	CcSEcCtD
Metaxalone—Rash—Pazopanib—kidney cancer	0.00862	0.00862	CcSEcCtD
Metaxalone—Nausea—Temsirolimus—kidney cancer	0.00862	0.00862	CcSEcCtD
Metaxalone—Dermatitis—Pazopanib—kidney cancer	0.00861	0.00861	CcSEcCtD
Metaxalone—Headache—Pazopanib—kidney cancer	0.00856	0.00856	CcSEcCtD
Metaxalone—Abdominal discomfort—Capecitabine—kidney cancer	0.00838	0.00838	CcSEcCtD
Metaxalone—Leukopenia—Vincristine—kidney cancer	0.00836	0.00836	CcSEcCtD
Metaxalone—Nausea—Pazopanib—kidney cancer	0.00812	0.00812	CcSEcCtD
Metaxalone—Hypersensitivity—Vinblastine—kidney cancer	0.00798	0.00798	CcSEcCtD
Metaxalone—Hypersensitivity—Everolimus—kidney cancer	0.00795	0.00795	CcSEcCtD
Metaxalone—Leukopenia—Gemcitabine—kidney cancer	0.00793	0.00793	CcSEcCtD
Metaxalone—Pruritus—Everolimus—kidney cancer	0.00763	0.00763	CcSEcCtD
Metaxalone—Anaphylactic shock—Vincristine—kidney cancer	0.00762	0.00762	CcSEcCtD
Metaxalone—Jaundice—Capecitabine—kidney cancer	0.00759	0.00759	CcSEcCtD
Metaxalone—Pruritus—Erlotinib—kidney cancer	0.00737	0.00737	CcSEcCtD
Metaxalone—Tension—Paclitaxel—kidney cancer	0.00728	0.00728	CcSEcCtD
Metaxalone—Anaphylactic shock—Gemcitabine—kidney cancer	0.00723	0.00723	CcSEcCtD
Metaxalone—Nervousness—Paclitaxel—kidney cancer	0.0072	0.0072	CcSEcCtD
Metaxalone—Dizziness—Vinblastine—kidney cancer	0.00716	0.00716	CcSEcCtD
Metaxalone—Dizziness—Everolimus—kidney cancer	0.00713	0.00713	CcSEcCtD
Metaxalone—Hypersensitivity—Sorafenib—kidney cancer	0.0069	0.0069	CcSEcCtD
Metaxalone—Vomiting—Vinblastine—kidney cancer	0.00689	0.00689	CcSEcCtD
Metaxalone—Dizziness—Erlotinib—kidney cancer	0.00688	0.00688	CcSEcCtD
Metaxalone—Vomiting—Everolimus—kidney cancer	0.00686	0.00686	CcSEcCtD
Metaxalone—Rash—Everolimus—kidney cancer	0.0068	0.0068	CcSEcCtD
Metaxalone—Dermatitis—Everolimus—kidney cancer	0.0068	0.0068	CcSEcCtD
Metaxalone—Headache—Vinblastine—kidney cancer	0.00679	0.00679	CcSEcCtD
Metaxalone—Headache—Everolimus—kidney cancer	0.00676	0.00676	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.00673	0.00673	CcSEcCtD
Metaxalone—Leukopenia—Paclitaxel—kidney cancer	0.00664	0.00664	CcSEcCtD
Metaxalone—Hypersensitivity—Sunitinib—kidney cancer	0.00664	0.00664	CcSEcCtD
Metaxalone—Pruritus—Sorafenib—kidney cancer	0.00663	0.00663	CcSEcCtD
Metaxalone—Vomiting—Erlotinib—kidney cancer	0.00662	0.00662	CcSEcCtD
Metaxalone—Rash—Erlotinib—kidney cancer	0.00656	0.00656	CcSEcCtD
Metaxalone—Dermatitis—Erlotinib—kidney cancer	0.00656	0.00656	CcSEcCtD
Metaxalone—Headache—Erlotinib—kidney cancer	0.00652	0.00652	CcSEcCtD
Metaxalone—Nausea—Vinblastine—kidney cancer	0.00643	0.00643	CcSEcCtD
Metaxalone—Somnolence—Gemcitabine—kidney cancer	0.00643	0.00643	CcSEcCtD
Metaxalone—Nausea—Everolimus—kidney cancer	0.00641	0.00641	CcSEcCtD
Metaxalone—Pruritus—Sunitinib—kidney cancer	0.00638	0.00638	CcSEcCtD
Metaxalone—Hypersensitivity—Dactinomycin—kidney cancer	0.00629	0.00629	CcSEcCtD
Metaxalone—Dizziness—Sorafenib—kidney cancer	0.00619	0.00619	CcSEcCtD
Metaxalone—Nausea—Erlotinib—kidney cancer	0.00618	0.00618	CcSEcCtD
Metaxalone—Anaphylactic shock—Paclitaxel—kidney cancer	0.00605	0.00605	CcSEcCtD
Metaxalone—Dizziness—Sunitinib—kidney cancer	0.00596	0.00596	CcSEcCtD
Metaxalone—Vomiting—Sorafenib—kidney cancer	0.00595	0.00595	CcSEcCtD
Metaxalone—Rash—Sorafenib—kidney cancer	0.00591	0.00591	CcSEcCtD
Metaxalone—Dermatitis—Sorafenib—kidney cancer	0.0059	0.0059	CcSEcCtD
Metaxalone—Headache—Sorafenib—kidney cancer	0.00587	0.00587	CcSEcCtD
Metaxalone—Vomiting—Sunitinib—kidney cancer	0.00573	0.00573	CcSEcCtD
Metaxalone—Rash—Sunitinib—kidney cancer	0.00568	0.00568	CcSEcCtD
Metaxalone—Dermatitis—Sunitinib—kidney cancer	0.00568	0.00568	CcSEcCtD
Metaxalone—Headache—Sunitinib—kidney cancer	0.00565	0.00565	CcSEcCtD
Metaxalone—Hypersensitivity—Vincristine—kidney cancer	0.00562	0.00562	CcSEcCtD
Metaxalone—Nausea—Sorafenib—kidney cancer	0.00556	0.00556	CcSEcCtD
Metaxalone—Leukopenia—Capecitabine—kidney cancer	0.00545	0.00545	CcSEcCtD
Metaxalone—Vomiting—Dactinomycin—kidney cancer	0.00542	0.00542	CcSEcCtD
Metaxalone—Somnolence—Paclitaxel—kidney cancer	0.00538	0.00538	CcSEcCtD
Metaxalone—Rash—Dactinomycin—kidney cancer	0.00538	0.00538	CcSEcCtD
Metaxalone—Nausea—Sunitinib—kidney cancer	0.00535	0.00535	CcSEcCtD
Metaxalone—Pruritus—Gemcitabine—kidney cancer	0.00512	0.00512	CcSEcCtD
Metaxalone—Nausea—Dactinomycin—kidney cancer	0.00507	0.00507	CcSEcCtD
Metaxalone—Dizziness—Vincristine—kidney cancer	0.00504	0.00504	CcSEcCtD
Metaxalone—Drowsiness—Doxorubicin—kidney cancer	0.00502	0.00502	CcSEcCtD
Metaxalone—Jaundice—Doxorubicin—kidney cancer	0.00489	0.00489	CcSEcCtD
Metaxalone—Vomiting—Vincristine—kidney cancer	0.00485	0.00485	CcSEcCtD
Metaxalone—Rash—Vincristine—kidney cancer	0.00481	0.00481	CcSEcCtD
Metaxalone—Dermatitis—Vincristine—kidney cancer	0.0048	0.0048	CcSEcCtD
Metaxalone—Headache—Vincristine—kidney cancer	0.00478	0.00478	CcSEcCtD
Metaxalone—Vomiting—Gemcitabine—kidney cancer	0.0046	0.0046	CcSEcCtD
Metaxalone—Rash—Gemcitabine—kidney cancer	0.00456	0.00456	CcSEcCtD
Metaxalone—Dermatitis—Gemcitabine—kidney cancer	0.00456	0.00456	CcSEcCtD
Metaxalone—Headache—Gemcitabine—kidney cancer	0.00453	0.00453	CcSEcCtD
Metaxalone—Nausea—Vincristine—kidney cancer	0.00453	0.00453	CcSEcCtD
Metaxalone—Hypersensitivity—Paclitaxel—kidney cancer	0.00446	0.00446	CcSEcCtD
Metaxalone—Nausea—Gemcitabine—kidney cancer	0.0043	0.0043	CcSEcCtD
Metaxalone—Pruritus—Paclitaxel—kidney cancer	0.00428	0.00428	CcSEcCtD
Metaxalone—Dizziness—Paclitaxel—kidney cancer	0.004	0.004	CcSEcCtD
Metaxalone—Tension—Doxorubicin—kidney cancer	0.00385	0.00385	CcSEcCtD
Metaxalone—Vomiting—Paclitaxel—kidney cancer	0.00385	0.00385	CcSEcCtD
Metaxalone—Rash—Paclitaxel—kidney cancer	0.00382	0.00382	CcSEcCtD
Metaxalone—Dermatitis—Paclitaxel—kidney cancer	0.00381	0.00381	CcSEcCtD
Metaxalone—Nervousness—Doxorubicin—kidney cancer	0.00381	0.00381	CcSEcCtD
Metaxalone—Headache—Paclitaxel—kidney cancer	0.00379	0.00379	CcSEcCtD
Metaxalone—Hypersensitivity—Capecitabine—kidney cancer	0.00366	0.00366	CcSEcCtD
Metaxalone—Nausea—Paclitaxel—kidney cancer	0.0036	0.0036	CcSEcCtD
Metaxalone—Pruritus—Capecitabine—kidney cancer	0.00351	0.00351	CcSEcCtD
Metaxalone—Leukopenia—Doxorubicin—kidney cancer	0.00351	0.00351	CcSEcCtD
Metaxalone—Dizziness—Capecitabine—kidney cancer	0.00329	0.00329	CcSEcCtD
Metaxalone—Anaphylactic shock—Doxorubicin—kidney cancer	0.0032	0.0032	CcSEcCtD
Metaxalone—Vomiting—Capecitabine—kidney cancer	0.00316	0.00316	CcSEcCtD
Metaxalone—Rash—Capecitabine—kidney cancer	0.00313	0.00313	CcSEcCtD
Metaxalone—Dermatitis—Capecitabine—kidney cancer	0.00313	0.00313	CcSEcCtD
Metaxalone—Headache—Capecitabine—kidney cancer	0.00311	0.00311	CcSEcCtD
Metaxalone—Nausea—Capecitabine—kidney cancer	0.00295	0.00295	CcSEcCtD
Metaxalone—Somnolence—Doxorubicin—kidney cancer	0.00285	0.00285	CcSEcCtD
Metaxalone—Hypersensitivity—Doxorubicin—kidney cancer	0.00236	0.00236	CcSEcCtD
Metaxalone—Pruritus—Doxorubicin—kidney cancer	0.00227	0.00227	CcSEcCtD
Metaxalone—Dizziness—Doxorubicin—kidney cancer	0.00212	0.00212	CcSEcCtD
Metaxalone—Vomiting—Doxorubicin—kidney cancer	0.00204	0.00204	CcSEcCtD
Metaxalone—Rash—Doxorubicin—kidney cancer	0.00202	0.00202	CcSEcCtD
Metaxalone—Dermatitis—Doxorubicin—kidney cancer	0.00202	0.00202	CcSEcCtD
Metaxalone—Headache—Doxorubicin—kidney cancer	0.00201	0.00201	CcSEcCtD
Metaxalone—Nausea—Doxorubicin—kidney cancer	0.0019	0.0019	CcSEcCtD
